The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies
Melanie Davies,1,2 Sudesna Chatterjee,1,2 Kamlesh Khunti1,2 1Diabetes Research Centre, University of Leicester, 2Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK Abstract: Worldwide, an estimated 200 million people have chronic kidney disease (CKD), the most com...
Guardado en:
Autores principales: | Davies M, Chatterjee S, Khunti K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1b8114630ba2446791b7106cce2b9f4a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
por: Helen Humphries, et al.
Publicado: (2021) -
A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
por: Maneesha Peter, et al.
Publicado: (2020) -
Differential renal adverse effects of ibuprofen and indomethacin in preterm infants: a review
por: Pacifici GM
Publicado: (2014) -
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
por: Ohanian M, et al.
Publicado: (2011) -
Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review
por: Aguirre Valadez J, et al.
Publicado: (2015)